TY - JOUR
T1 - Lack of association between MAGEL2 and schizophrenia and mood disorders in the Japanese population
AU - Fukuo, Yasuhisa
AU - Kishi, Taro
AU - Okochi, Tomo
AU - Kitajima, Tsuyoshi
AU - Tsunoka, Tomoko
AU - Okumukura, Takenori
AU - Kinoshita, Yoko
AU - Kawashima, Kunihiro
AU - Yamanouchi, Yoshio
AU - Umene-Nakano, Wakako
AU - Naitoh, Hiroshi
AU - Inada, Toshiya
AU - Yoshimura, Reiji
AU - Nakamura, Jun
AU - Ozaki, Norio
AU - Iwata, Nakao
N1 - Funding Information:
Acknowledgments We thank Ms M Miyata and Ms S Ishihara for their technical support. This work was supported in part by research grants from the Ministry of Education, Culture, Sports, Science and Technology, the Ministry of Health, Labor and Welfare, and the Japan Health Sciences Foundation (Research on Health Sciences focusing on Drug Innovation).
PY - 2010/9
Y1 - 2010/9
N2 - Several investigations have reported that abnormalities in circadian rhythms might be related with the pathophysiology of psychiatric disorders, since many psychiatric patients have insomnia and sleep-awake disturbance. A recent animal study reported that Magel2, which encodes a member of the MAGE/necdin family of proteins, might be associated in the pathophysiology of psychiatric disorders. Magel2 gene knockout mice showed altered concentrations of both dopamine and serotonin in several parts of the brain compared with controls. In addition, the authors of that study detected a bilateral reduction in cortical volume in distinct regions of the Magel2 gene knockout mice brain, including focused regions in the parieto-temporal lobe of the cerebral cortex, the amygdala, the hippocampus, and the nucleus accumbens. These mice were also found to have hypoactivity and abnormalities in circadian rhythms. From this evidence, we considered Magel2 gene (MAGEL2) to be a good candidate gene for the pathophysiology of schizophrenia and mood disorder, and we conducted a case-control study among Japanese (731 schizophrenia patients, 465 MDD patients, 156 BP patients and 758 controls) using three tagging SNPs in MAGEL2 (rs850815, rs8920 and rs4480754), selected using the HapMap database. We did not find any association between MAGEL2 and schizophrenia, BP or MDD in allele/genotype-wise analysis or haplotype-wise analysis. Our results suggest that MAGEL2 may not play a role in the pathophysiology of schizophrenia and mood disorders in the Japanese population. A replication study using larger samples may be required for conclusive results, since our sample size was small and our study analyzed only three SNPs in MAGEL2.
AB - Several investigations have reported that abnormalities in circadian rhythms might be related with the pathophysiology of psychiatric disorders, since many psychiatric patients have insomnia and sleep-awake disturbance. A recent animal study reported that Magel2, which encodes a member of the MAGE/necdin family of proteins, might be associated in the pathophysiology of psychiatric disorders. Magel2 gene knockout mice showed altered concentrations of both dopamine and serotonin in several parts of the brain compared with controls. In addition, the authors of that study detected a bilateral reduction in cortical volume in distinct regions of the Magel2 gene knockout mice brain, including focused regions in the parieto-temporal lobe of the cerebral cortex, the amygdala, the hippocampus, and the nucleus accumbens. These mice were also found to have hypoactivity and abnormalities in circadian rhythms. From this evidence, we considered Magel2 gene (MAGEL2) to be a good candidate gene for the pathophysiology of schizophrenia and mood disorder, and we conducted a case-control study among Japanese (731 schizophrenia patients, 465 MDD patients, 156 BP patients and 758 controls) using three tagging SNPs in MAGEL2 (rs850815, rs8920 and rs4480754), selected using the HapMap database. We did not find any association between MAGEL2 and schizophrenia, BP or MDD in allele/genotype-wise analysis or haplotype-wise analysis. Our results suggest that MAGEL2 may not play a role in the pathophysiology of schizophrenia and mood disorders in the Japanese population. A replication study using larger samples may be required for conclusive results, since our sample size was small and our study analyzed only three SNPs in MAGEL2.
UR - http://www.scopus.com/inward/record.url?scp=78649952852&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78649952852&partnerID=8YFLogxK
U2 - 10.1007/s12017-010-8116-8
DO - 10.1007/s12017-010-8116-8
M3 - Article
C2 - 20467835
AN - SCOPUS:78649952852
SN - 1535-1084
VL - 12
SP - 285
EP - 291
JO - NeuroMolecular Medicine
JF - NeuroMolecular Medicine
IS - 3
ER -